ORIC Pharmaceuticals stock trades 10.7 percent below its 52-week high

ORIC Pharmaceuticals stock was trading at USD 13.33 on Nasdaq on September 23, 2026, down USD 0.17 or 1.26 percent from the prior close. The price stood 10.7 percent below the 52-week high of USD 14.93, making the company's clinical milestones the central valuation reference.

Phase 3 sets the timetable

ORIC has started Himalayas-1, a global Phase 3 study of rinzimetostat in prostate cancer patients previously treated with abiraterone. The trial is designed to enroll 600 patients, with top-line data expected in the first half of 2028, according to Investing.com on September 10, 2026.

The study design gives the stock a milestone-driven profile: the next major value test is clinical execution rather than a near-term sales cycle. ORIC is also advancing enozertinib for EGFR-mutated non-small cell lung cancer, adding a second late-stage development path, per ORIC Pharmaceuticals in its September 2, 2026 release.

Cash supports the trial push

ORIC held USD 387.6 million in cash and investments after the second quarter, according to Yahoo Finance on September 15, 2026. That balance is the financial counterweight to the trial risk and supports the company's plan to run Himalayas-1 while preparing additional development work.

Second-quarter diluted loss was USD 0.38 per share, compared with a consensus loss of USD 0.36, according to MarketBeat in a September 13, 2026 report. The USD 0.02 per-share miss keeps cash burn relevant even as the pipeline moves into more advanced testing.

Stock stays below yearly high

ORIC Pharmaceuticals stock was trading at USD 13.33 on Nasdaq on September 23, 2026. Its 52-week range was USD 7.23 to USD 14.93, while market capitalization stood at USD 1,379,889,101 on the same date.